Seribantumab

Monoclonal antibody

Pharmaceutical compound

Seribantumab
Monoclonal antibody
Type	?
Source	Human
Target	HER3
Clinical data
Other names	MM-121
ATC code	none
Identifiers
CAS Number	1334296-12-6
IUPHAR/BPS	8297
ChemSpider	none
UNII	1N3L70MDFX
KEGG	D11777
Chemical and physical data
Formula	C₆₃₄₀H₉₈₁₀N₁₆₉₀O₁₉₈₆S₅₂
Molar mass	143151.18 g·mol⁻¹

Seribantumab (INN;^[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.^[2] It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.^[3]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

[edit ]

^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association .
^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi:10.3390/biomedicines10092113 . PMC 9495728 . PMID 36140214.

Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

v
t
e

v
t
e

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab ^§ Amivantamab Ascrinvacumab ^§ Atezolizumab (+hyaluronidase) Balstilimab ^† Botensilimab Cixutumumab ^§ Conatumumab ^§ Cosibelimab Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin Enoticumab ^§ Figitumumab ^§ Flanvotumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Linvoseltamab Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Nivolumab ^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pembrolizumab ^# Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Sugemalimab Tarextumab ^§ Tisotumab vedotin Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab ^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ecromeximab ^§ Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab ^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab ^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Datopotamab deruxtecan Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab Emibetuzumab ^§ Enoblituzumab ^§ Epcoritamab Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab ^§ Inotuzumab ozogamicin Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Naxitamab Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Odronextamab Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan Sibrotuzumab ^§ Simtuzumab ^§ Sofituzumab vedotin ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab ^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab ^§
Chimeric + humanized	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v
t
e

Growth factor receptor modulators

Angiopoietin

Agonists: Angiopoietin 1
Angiopoietin 4

Antagonists: Angiopoietin 2
Angiopoietin 3

Kinase inhibitors: Altiratinib
CE-245677
Rebastinib

Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)

CNTF

Agonists: Axokine
CNTF
Dapiclermin

EGF (ErbB)

EGF (ErbB1/HER1)	Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors: Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab
ErbB2/HER2	Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib Lapatinib Mubritinib Neratinib Tucatinib
ErbB3/HER3	Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies: Duligotumab Patritumab Seribantumab
ErbB4/HER4	Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGF

FGFR1	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Selpercatinib Trafermin Velafermin
FGFR2	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Selpercatinib Sprifermin Trafermin Antibodies: Aprutumab Aprutumab ixadotin Kinase inhibitors: Infigratinib
FGFR3	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23)
FGFR4	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin
Unsorted	Agonists: FGF15/19

HGF (c-Met)

Agonists: Fosgonimeton
Hepatocyte growth factor

Potentiators: Dihexa (PNB-0408)

IGF

IGF-1	Agonists: des(1-3)IGF-1 Insulin-like growth factor-1 (somatomedin C) IGF-1 LR3 Insulin-like growth factor-2 (somatomedin A) Insulin Mecasermin Mecasermin rinfabate Kinase inhibitors: BMS-754807 Linsitinib NVP-ADW742 NVP-AEW541 OSl-906 Antibodies: AVE-1642 Cixutumumab Dalotuzumab Figitumumab Ganitumab Robatumumab R1507 Teprotumumab Xentuzumab (against IGF-1 and IGF-2)
IGF-2	Agonists: Insulin-like growth factor-2 (somatomedin A) Antibodies: Dusigitumab Xentuzumab (against IGF-1 and IGF-2)
Others	Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7) Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1) Trofinetide

LNGF (p75^NTR)

Antibodies: Against NGF: ABT-110 (PG110)
ASP-6294
Fasinumab
Frunevetmab
Fulranumab
MEDI-578
Ranevetmab
Tanezumab

Aptamers: Against NGF: RBM-004

Decoy receptors: LEVI-04 (p75^NTR-Fc)

PDGF

Agonists: Becaplermin
Platelet-derived growth factor (A, B, C, D)

RET (GFL)

GFRα1	Agonists: Glial cell line-derived neurotrophic factor (GDNF) Liatermin Kinase inhibitors: Vandetanib
GFRα2	Agonists: Neurturin (NRTN) Kinase inhibitors: Vandetanib
GFRα3	Agonists: Artemin (ARTN) Kinase inhibitors: Vandetanib
GFRα4	Agonists: Persephin (PSPN) Kinase inhibitors: Vandetanib
Unsorted	Kinase inhibitors: Agerafenib

SCF (c-Kit)

Agonists: Ancestim
Stem cell factor

TGFβ

See here instead.

Trk

TrkA	Agonists: Amitriptyline BNN-20 BNN-27 Cenegermin DHEA DHEA-S Gambogic amide NGF Tavilermide Antagonists: ALE-0540 Dexamethasone FX007 Testosterone Negative allosteric modulators: VM-902A Kinase inhibitors: Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556 PLX-7486 Rebastinib SNA-120 (pegylated K252a)) Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers: Against NGF: RBM-004 Decoy receptors: ReN-1820 (TrkAd5)
TrkB	Agonists: 3,7-DHF 3,7,8,2'-THF 4'-DMA-7,8-DHF 7,3'-DHF 7,8-DHF 7,8,2'-THF 7,8,3'-THF Amitriptyline BDNF BNN-20 Deoxygedunin Deprenyl Diosmetin DMAQ-B1 HIOC LM22A-4 N-Acetylserotonin NT-3 NT-4 Norwogonin (5,7,8-THF) R7 R13 TDP6 Antagonists: ANA-12 Cyclotraxin B Gossypetin (3,5,7,8,3',4'-HHF) Ligands: DHEA Kinase inhibitors: Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib ONO-4474 ONO-5390556 PLX-7486
TrkC	Agonists: BNN-20 DHEA NT-3 Kinase inhibitors: Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051 Entrectinib GZ-389988 K252a Larotrectinib Lestaurtinib ONO-4474 ONO-5390556 PLX-7486

VEGF

Agonists: Placental growth factor (PGF)
Ripretinib
Telbermin
VEGF (A, B, C, D (FIGF))

Allosteric modulators: Cyclotraxin B

Decoy receptors: Aflibercept

Others

Additional growth factors: Adrenomedullin
Colony-stimulating factors (see here instead)
Connective tissue growth factor (CTGF)
Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
Erythropoietin (see here instead)
Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
Glia maturation factor (GMF)
Hepatoma-derived growth factor (HDGF)
Interleukins/T-cell growth factors (see here instead)
Leukemia inhibitory factor (LIF)
Macrophage-stimulating protein (MSP; HLP, HGFLP)
Midkine (NEGF2)
Migration-stimulating factor (MSF; PRG4)
Oncomodulin
Pituitary adenylate cyclase-activating peptide (PACAP)
Pleiotrophin
Renalase
Thrombopoietin (see here instead)
Wnt signaling proteins

Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Seribantumab&oldid=1188037068"